Results 181 to 190 of about 407,619 (292)

Lanadelumab in Hereditary Angioedema: Real-World Outcomes and Implications for Access Practices in Europe. [PDF]

J Clin Med
Różyk D, Wrona W, Kucharczyk B, Tomaszewska A, Kucharczyk A.   +4 more
europepmc   +1 more source

Impact of lung cancer screening eligibility criteria on participants' characteristics and healthcare resources

International Journal of Cancer, EarlyView.
What's New? Inclusion criteria for lung cancer screening (LCS) maintain cost control by focusing resources on select high‐risk groups. However, eligible individuals are inherently dissimilar in risk profile and demographics, potentially impacting LCS effectiveness and uptake.
María Olivia Cabrera, Kevin ten Haaf, Josep Maria Borràs, Rebeca Font, Judit Solà, Juul Hubert, Mónica Ballesteros, Josep Alfons Espinàs   +7 more
wiley   +1 more source

Nationwide Survival Impact of Bevacizumab Under National Reimbursement for Advanced Cervical Cancer in South Korea. [PDF]

Cancers (Basel)
Kim J, Jang J, Tewari KS, Kim KS, Kang HC, Kang S.   +5 more
europepmc   +1 more source

Researching Supply Reimbursement [PDF]

Ear, Nose & Throat Journal, 2005
openaire   +2 more sources

Indicators to identify cancer screening providers with suboptimal case detection: A scoping review

International Journal of Cancer, EarlyView.
What's New? Quality control of cancer screening programs is essential to maintaining high public health standards. Here, the authors reviewed monitoring of case detection in cervical and colorectal cancer screening programs in Europe, and evaluated its effectiveness. They analysed 20 different measures used for this purpose and showed that many of them
Jiayao Lei, Milena Falcaro, Adam R. Brentnall, James F. O'Mahony, Sisse Helle Njor, Matejka Rebolj   +5 more
wiley   +1 more source

Breast and cervical cancer care in Ghana: a qualitative exploratory study of stakeholder perspectives on National Health Insurance Scheme coverage. [PDF]

BMJ Open
Amankwah I, Gone M, Jaliu A, Morand M, Owusu R.   +4 more
europepmc   +1 more source

Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to IMDC risk criteria—A multi‐center retrospective analysis on behalf of the GUARDIANS group

International Journal of Cancer, EarlyView.
What's New? The combination of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma has demonstrated durable response and tolerability in clinical trials. However, inclusion criteria for clinical studies are restrictive, and patients in the real‐world setting tend to have more comorbidities.
Hendrik Dinkel, Linus Materna, Ramona Stelmach, Stefanie Zschäbitz, Stephanie Neuberger, Can D. Aydogdu, Jozefina Casuscelli, Timo Egenolf, Matteo Silberg, Julie Steinestel, Arne Strauss, Florian Kirchhoff, Marit Ahrens, Pia Paffenholz, Richard Cathomas, Berna C. Özdemir, Christopher Gossler, Philipp Ivanyi, Marc Rehlinghaus, Thomas Hilser, Viktor Grünwald, Katrin Schlack   +21 more
wiley   +1 more source

Epidemiological evidence for the role of puberty and immune senescence in Hodgkin lymphoma aetiology from 1992 Danish cases

International Journal of Cancer, EarlyView.
What's New? The understanding of the epidemiological and clinical distinctions between Epstein–Barr virus (EBV)‐positive and EBV‐negative classic Hodgkin lymphoma remains incomplete. Here, the authors generated unique sets of population‐based sex‐ and age‐specific incidence rates of classic Hodgkin lymphoma in Denmark stratified by histological subtype
Klaus Rostgaard, Stephen Hamilton‐Dutoit, Kristina L. Lauridsen, Lisa Ottander, Trine L. Plesner, Peter Hollander, Peter Brown, Lene Sjö, Christoffer Johansen, Peter Kamper, Estrid Høgdall, Francesco d'Amore, Lena Specht, Ruth F. Jarrett, James D. McKay, Martin Hutchings, Lisa L. Hjalgrim, Ingrid Glimelius, Henrik Hjalgrim   +18 more
wiley   +1 more source

Tissue and organ engineering: Investor sentiments and analysis. [PDF]

Regen Ther
Velcani F, Keyes E, Caraveo JL, Reohr J, D'Cruz C, Osterman A, O'Donnell DC.   +6 more
europepmc   +1 more source

Global patterns and trends in kidney cancer incidence and mortality

International Journal of Cancer, EarlyView.
What's New? Decreasing mortality from kidney cancer in developed countries contrasts with persistently high or rising mortality in less‐developed regions. Factors underlying this widening gap remain incompletely understood. Using GLOBOCAN 2022 data, the present study examined patterns in kidney cancer incidence and mortality worldwide and the relation ...
Anton Barchuk, Jerome Vignat, Kari A. O. Tikkinen, Ahmedin Jemal, Freddie Bray, Ariana Znaor   +5 more
wiley   +1 more source